US EditionML Enhanced Bioactivity Prediction for Angiotensin II Receptor: A Potential Anti-Hypertensive Drug Target
SUZHOU, CHINA, JUL 15 – Divamics' AI and molecular dynamics platform supports novel metabolic disease drugs, including two candidates in Phase III trials, improving drug discovery efficiency, company said.
- Monday in Suzhou, China, Divamics highlighted its AI and molecular dynamics platform's role in advancing metabolic disease therapeutics.
- Backed by a proven track record, Divamics' platform supported two candidates in Phase III trials since 2024 with its AI and molecular dynamics technology.
- In the July 2025 issue of the Journal of Medicinal Chemistry, the design of BGM1812 was published, and preclinical studies confirmed a 50% potency boost with significant weight loss.
- Through partnerships, Dr. John Zheng said `redefining how our partners can approach previously 'undruggable' targets`, demonstrating the platform’s impact.
- Building on early wins, Divamics' platform indicates the potential to redefine discovery efficiency and empower partners’ pipelines.
65 Articles
65 Articles
InsideNoVA.com
Divamics' AI and Molecular Dynamics Platform Powers Breakthroughs in Metabolic Disease Drug Discovery for Partners
SUZHOU, China, July 14, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform. This powerful platform recently supported the successful design of…
ML enhanced bioactivity prediction for angiotensin II receptor: A potential anti-hypertensive drug target
The process of drug discovery is intricate, and encompasses a series of detailed phases of research, development, and testing, aimed at evaluating the safety and effectiveness of prospective therapeutic agents. Artificial Intelligence has emerged as a transformative tool in this domain, adept at analysing vast datasets to uncover intricate patterns and relationships unperceivable to humans. This study introduces a bioactivity prediction applicat…
Divamics AI Platform Drives Metabolic Disease Drug Discovery - AI-Tech Park
Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform. This powerful platform recently supported the successful design of BGM1812, a novel dual AMY3R/CTR receptor agonist for obesity treatment, as published in the July 2025 issue of the Journal of Medicinal Chemistry. This achievement underscores Divamics’ consistent a…
Divamics Fuels Drug Discovery with AI-Powered Metabolic Disease Platform
SUZHOU, China, July 15, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform. This powerful platform recently supported the successful design of BGM1812, a novel dual AMY3R/CTR receptor agonist for obesity treatment, as published in the July 2025 issue of the Journal of Medicinal Chemistry. This a…
Coverage Details
Bias Distribution
- 59% of the sources are Center
To view factuality data please Upgrade to Premium
